Amlypave

RSS

Application withdrawn

The application for this medicine has been withdrawn

anselamimab
MedicineHumanApplication withdrawn

Italian is available via eTranslation, the European Commission's machine translation service.

Translate to Italian | Important information about machine translation

  • Application under evaluation
  • Withdrawal of application

Overview

Alexion Europe withdrew its application for a marketing authorisation of Amlypave for treating kappa light chain amyloidosis that seriously affects the heart.

The company withdrew the application on 30 October 2026.

Amlypave was developed for treating adults with newly diagnosed Mayo stage IIIa and IIIb kappa light chain amyloidosis.

Kappa light chain amyloidosis is a disease in which proteins (kappa light chains) form clumps called amyloids that build up in tissues and organs, such as the heart, and prevent them from working properly.

Amlypave was intended for adults with serious effects on the heart (Mayo stage IIIa and IIIb) caused by the amyloid clumps.

Amlypave contains the active substance anselamimab and was to be available as a concentrate for making a solution for infusion (drip) into a vein.

Amlypave was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 13 November 2019 for the treatment of AL amyloidosis. 

The active substance in Amlypave, anselamimab, is a monoclonal antibody, a type of protein designed to attach to abnormal kappa light chain proteins. By attaching to them, anselamimab was expected to help the immune system remove the amyloid deposits from tissues and organs and reduce the damage they cause.

The company presented results from two main studies involving a total of 406 adults with newly diagnosed Mayo stage IIIa or IIIb light chain amyloidosis, including 72 patients with kappa light chain amyloidosis. In these studies, the patients received Amlypave or placebo (a dummy treatment) in addition to standard treatment. The main measure of effectiveness was based on how long patients lived and how often they were admitted to hospital because of cardiovascular problems. 

The application was withdrawn after the European Medicines Agency had evaluated the information from the company and prepared questions for the company. After the Agency had assessed the company’s responses to the last round of questions, there were still some unresolved issues.

Based on the review of the data and the company’s responses to the Agency’s questions, at the time of the withdrawal, the Agency had some concerns and its provisional opinion was that Amlypave should not be authorised for the treatment of newly diagnosed Mayo stage IIIa and IIIb kappa light chain amyloidosis.

This provisional opinion was based on the fact that the main studies were not able to show that Amlypave was more effective than placebo in the overall group of patients, and there was insufficient evidence that it would be effective in the smaller subgroup of patients with kappa light chain amyloidosis. Therefore, at the time of the withdrawal, the Agency’s opinion was that, because effectiveness was not proven, the benefits of Amlypave did not outweigh its risks.

In its letter notifying the Agency of the withdrawal of the application, the company stated that it had decided to generate further data taking into account feedback from the Agency.

The company informed the Agency that there are no consequences for patients in clinical trials using Amlypave.

If you are in a clinical trial and need more information about your treatment, speak with your clinical trial doctor.

Key facts

Name of medicine
Amlypave
Active substance
anselamimab
International non-proprietary name (INN) or common name
anselamimab
Therapeutic area (MeSH)
Immunoglobulin Light-chain Amyloidosis
Anatomical therapeutic chemical (ATC) code
B06AX
EMA product number
EMEA/H/C/006422

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Marketing authorisation applicant
Alexion Europe
Withdrawal of application
30/10/2026

All documents

This page was last updated on

Share this page